MedTrace Logo

Effect of MK0524A on Flushing Caused by Niacin (0524A-056)

NCT00533611 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 330

Last updated 2017-02-17

No results posted yet for this study

Summary

The primary objective of the study is to assess the effects of MK0524A in reducing flushing associated with niacin.

Conditions

  • Flushing

Interventions

DRUG

MK0524A, /Duration of Treatment : 4 Weeks

DRUG

Comparator : niacin /Duration of Treatment : 1 Weeks

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2007-08-31
Completion
2007-08-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00533611 on ClinicalTrials.gov